Company intelligence / Profile preview

Hong Kong King-Friend Industrial

Hong Kong, Hong Kong SARnkf-pharma.com ↗

Ownership: Private
Development stage: Other

Overview

HKF, as a subsidiary of Nanjing King-Friend, is a key international commercialization and distribution arm with several US FDA-approved generics, injectables, and biosimilars—including US launches such as eptifibatide and biosimilars for adalimumab, filgrastim, pegfilgrastim, and follitropin alpha—serving critical care, fertility, and autoimmune indications across multiple global regions[1][2][3][4][8].

Therapeutic areas: ImmunologyNephrologyRheumatologyGastroenterologyPulmonologyDermatologyCardiovascularOncologyNeurologyWomen's Health
Modalities: Small moleculeBiologicBiosimilarPeptideMonoclonal antibody
Industry: Biotech

Partnerships

Meitheal Pharmaceuticals (exclusive US commercialization partner)Coherus (biosimilar commercialization - Yusimry)Livzon (distribution/export cooperation)

Beyond the preview

Go deeper on Hong Kong King-Friend Industrial.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hong Kong King-Friend Industrial.